How many dengue cases did Brazil have in 2024?

Brazil recorded a catastrophic dengue epidemic in early 2024, with over 4 million cases reported in the first half of the year alone — the worst outbreak in Brazilian history. More than 1,500 deaths were attributed to dengue in the 2024 outbreak.

Which serotype is dominant in Brazil?

DENV-3 re-emerged as the dominant serotype in Brazil's 2024 outbreak after years of DENV-2 dominance. This serotype shift was significant because large portions of the population lacked immunity to DENV-3, enabling explosive spread and higher rates of severe dengue.

What is the Wolbachia program in Brazil?

The World Mosquito Program has deployed Wolbachia-infected Aedes aegypti mosquitoes in parts of Rio de Janeiro and other Brazilian cities. Wolbachia-carrying mosquitoes have reduced dengue transmission capacity. A landmark trial in Yogyakarta, Indonesia showed 77% reduction — Brazilian cities are seeing similar results in treated areas.

Is dengue vaccine available in Brazil?

Both Dengvaxia and Takeda's Qdenga (TAK-003) are licensed in Brazil. Qdenga was incorporated into Brazil's National Immunization Program (NIP) in 2024 for children and adolescents aged 10–14 years as part of the response to the record outbreak.

BrazilDengueSouth America

Dengue Fever in Brazil: The World's Largest National Outbreak

Brazil reported over 4 million dengue cases in early 2024 — the worst outbreak in history — driven by a serotype shift, climate factors, and urban mosquito breeding.

VirusWatch Editorial Team — Last reviewed: May 2025

Medical Disclaimer: Educational content only. For dengue fever, use only paracetamol — NEVER ibuprofen or aspirin.

The 2024 Record Epidemic

Brazil declared a public health emergency in February 2024 as dengue cases surged to unprecedented levels. By mid-2024, more than 4 million cases had been confirmed — exceeding any previous full-year total. Deaths exceeded 1,500. The state of Minas Gerais was hardest hit, along with São Paulo, Paraná, and the Federal District (Brasília).

The dominant driver of the 2024 surge was the return of DENV-3 as the dominant serotype after nearly a decade of DENV-2 prevalence. A large portion of the Brazilian population — particularly those born after 2003 when DENV-3 last dominated — had no immunity to this serotype. Combined with above-average temperatures from El Niño and record urban mosquito populations, the conditions for a catastrophic outbreak were set.

Key Epidemiological Data

Metric	Data
2024 cases (reported)	>4 million (record)
2024 deaths	>1,500
Hardest-hit states	Minas Gerais, São Paulo, Paraná, DF
Dominant serotype (2024)	DENV-3 (re-emergence)
Peak season	January–May (Brazilian summer/rainy season)

Why Brazil Is So Vulnerable

Climate: Hot, humid tropical and subtropical climate ideal for Aedes aegypti year-round in most states
Urbanization: Over 85% of Brazilians live in cities; dense favela populations with inadequate sanitation create breeding sites
Serotype cycling: All 4 DENV serotypes circulate; serotype shifts create large naive populations
Climate change: Higher temperatures extending the dengue season and expanding vector range southward
El Niño years: Above-average rainfall and temperatures correlate strongly with dengue epidemics

Brazil's Response Innovations

Wolbachia Program (World Mosquito Program): Brazil is one of the leading deployment sites for Wolbachia-infected Aedes aegypti mosquitoes. In Niterói (Greater Rio de Janeiro area), Wolbachia mosquitoes have been released and are now established in local mosquito populations. Early data from Brazilian deployment sites show significant reductions in dengue incidence in treated neighborhoods.

Qdenga vaccination: Brazil became the first country to incorporate the Takeda Qdenga (TAK-003) dengue vaccine into its National Immunization Program in 2024, targeting children and adolescents aged 10–14 years. This is a landmark step — Qdenga does not require prior dengue testing and is effective in both seropositive and seronegative individuals, avoiding the safety concerns of Dengvaxia.

GM mosquitoes: OX513A, a genetically modified Aedes aegypti strain developed by Oxitec, has been field-tested in Brazil. Male GM mosquitoes mate with females; offspring carry a lethal gene and die before maturity, reducing mosquito populations.

Prevention for Travelers and Residents

Use DEET (20–30%) or picaridin repellent during daylight hours
Wear long-sleeved shirts and long trousers
Stay in air-conditioned or well-screened accommodations
Eliminate standing water around your home weekly
Seek immediate medical care for any fever — ask for an NS1 antigen dengue test
ONLY use paracetamol for fever — ibuprofen and aspirin are contraindicated

Get Dengue Outbreak Alerts

Be notified when dengue outbreaks are reported in Brazil and South America.

Frequently Asked Questions

Three converging factors: (1) Re-emergence of DENV-3 serotype after a decade of DENV-2 dominance, leaving a large non-immune population; (2) El Niño causing higher-than-normal temperatures and rainfall, boosting mosquito populations; (3) Ongoing urbanization and inadequate waste/water management sustaining mosquito breeding sites.

Yes. Brazil's National Immunization Program incorporated Qdenga (TAK-003) in 2024 for ages 10–14. Dengvaxia is also licensed but only recommended for previously infected individuals. The public program uses Qdenga, which doesn't require prior testing.

The World Mosquito Program releases Aedes aegypti mosquitoes infected with Wolbachia bacteria, which blocks dengue virus replication inside the mosquito. Wolbachia spreads through the mosquito population naturally. Cities in Brazil and elsewhere with high Wolbachia deployment have seen 40–77% reductions in dengue cases.

Sources: Brazil Ministry of Health epidemiological bulletins; PAHO dengue situation reports; WHO PAHO Americas dengue data; World Mosquito Program Brazil results; Lancet 2024 Qdenga NIP implementation.